HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Clinical trials for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR POSITIVE/HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HR POSITIVE/HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune drug combo aims to wipe out breast tumors before surgery
Disease control Not yet recruitingThis study tests whether adding an immune-boosting drug called eftilagimod alpha to standard chemotherapy can make breast tumors disappear completely before surgery in people with early-stage HR+/HER2- breast cancer. About 50 participants will receive the drug combination, and re…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: George Washington University • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
New drug targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Not yet recruitingThis early-phase study tests an experimental drug, CGT6297, in adults with advanced solid tumors (like certain breast and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to find a safe dose and see if the drug can shrink tumors. About 90…
Matched conditions: HR POSITIVE/HER-2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated May 20, 2026 11:53 UTC